Aquestive Therapeutics, Inc. (AQST) Analysts See $-0.49 EPS

November 11, 2018 - By Marie Mckinney

Analysts expect Aquestive Therapeutics, Inc. (NASDAQ:AQST) to report $-0.49 EPS on December, 4.After having $-1.90 EPS previously, Aquestive Therapeutics, Inc.’s analysts see -74.21 % EPS growth. The stock decreased 5.56% or $1 during the last trading session, reaching $17. About 47,544 shares traded. Aquestive Therapeutics, Inc. (NASDAQ:AQST) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company has market cap of $424.01 million. The Company’s products are developed using its PharmFilm technology. It currently has negative earnings. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

More notable recent Aquestive Therapeutics, Inc. (NASDAQ:AQST) news were published by: which released: “74 Biggest Movers From Friday” on November 05, 2018, also with their article: “Aquestive Therapeutics Inc. (AQST) Reports Positive Topline Results for Complete Diazepam Buccal Film Adult …” published on October 25, 2018, published: “Aquestive Therapeutics (AQST) Announces FDA Approval for SYMPAZAN Oral Film” on November 02, 2018. More interesting news about Aquestive Therapeutics, Inc. (NASDAQ:AQST) were released by: and their article: “The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos …” published on November 06, 2018 as well as‘s news article titled: “Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights” with publication date: November 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.